Newer hepatitis C (HCV) drugs have shown very good sustained viral response rates and little risk of resistance-associated substitutions, David L. Wyles, M.D., reported in a webinar.
To help clinicians and patients navigate the challenges of HIV/HCV coinfection, AETC NCRC released an infographic that addresses the most common barriers preventing HIV-positive people from curing their HCV infection.
A Cochrane review of new hepatitis C drugs has discredited what can be a useful process for combining results from multiple studies, and irresponsible reporting of the review risks limiting access to effective treatment.
Over just five years, the number of new hepatitis C virus infections reported to the U.S. CDC has nearly tripled, reaching a 15-year high.
The first study of hepatitis C incidence and injecting behavior across cities and over 25 years showed the differences in incidence reflect differences in policies to reduce the harm of injecting drug use.
"The new screening guidelines ignore expert advice regarding who should be tested for hep C, setting a dangerous public health policy where dollars come first and the health of Canadians comes last."
The 2017 Synchronicity Conference, a national conference that focuses on HIV and hepatitis C, also addressed LGBT health for the first time this year.
With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure.
Nearly three-quarters of HIV/hepatitis C (HCV)-coinfected drug users reported willingness to use direct-activing antivirals (DAAs) for HCV, a substantial improvement over the willingness of this group to use interferon-based regimens.